Turkmenistan Health News: Press Releases

Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Turkmenistan Health News.

December 2025

Mo	Tu	We	Th	Fr	Sa	Su
1	2	3	4	5	6	7
8	9	10	11	12	13	14
15	16	17	18	19	20	21
22	23	24	25	26	27	28
29	30	31

January 2026

Mo	Tu	We	Th	Fr	Sa	Su
			1	2	3	4
5	6	7	8	9	10	11
12	13	14	15	16	17	18
19	20	21	22	23	24	25
26	27	28	29	30	31

February 2026

Mo	Tu	We	Th	Fr	Sa	Su
						1
2	3	4	5	6	7	8
9	10	11	12	13	14	15
16	17	18	19	20	21	22
23	24	25	26	27	28

Press releases published on February 6, 2026

an hour ago

Do'Mo Highlights Cultural Shift Towards Sober Dating as Valentine's Day 2026 Approaches

GlobeNewswire

2 hours ago

Novartis breaks ground on new global Biomedical Research center in San Diego to accelerate drug discovery

GlobeNewswire

3 hours ago

R1 Appoints Andy Brailo as Chief Commercial Officer

GlobeNewswire

3 hours ago

Global Markets Accelerate with CAGRs Approaching 20% Through 2030

GlobeNewswire

5 hours ago

Global AI in Hospital Operations Market Set to Surge to USD 25.70 Billion by 2030 | MarketsandMarkets™

GlobeNewswire

5 hours ago

Ernexa Therapeutics Announces Pricing of $10.5 Million Public Offering

GlobeNewswire

5 hours ago

SRx Health Solutions Launches EventHorizonIQ, a Public Ledger of AI-Generated Financial Market Instability Signals

GlobeNewswire

5 hours ago

AIM ImmunoTech to Participate in the Corporate Connect Webinar Series Virtual Conference Hosted by Webull Financial

GlobeNewswire

6 hours ago

Shattuck Labs Announces Participation in Upcoming Piper Sandler Virtual Novel Targets in Immunology Symposium

GlobeNewswire

6 hours ago

Hopebridge Announces Retirement of CEO Dennis May After a Decade of Leadership

GlobeNewswire

6 hours ago

Solid Biosciences to Present at the Guggenheim Emerging Outlook: Biotech Summit 2026

GlobeNewswire

6 hours ago

Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire

6 hours ago

Immutep Achieves 50% Enrolment in Global TACTI-004 (KEYNOTE-F91) Phase III Trial in 1L NSCLC

GlobeNewswire

6 hours ago

Clearmind Medicine Enters into Development Agreement to Advance Intranasal Formulation for its Proprietary Non-Hallucinogenic Neuroplastogen MEAI

GlobeNewswire

6 hours ago

Polyrizon Signs an Agreement to Develop Intranasal Proprietary Non-Hallucinogenic Neuroplastogen Formulation

GlobeNewswire

7 hours ago

Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire

7 hours ago

Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire

7 hours ago

TG Therapeutics Announces Presentation of Data for BRIUMVI® (ublituximab) in Multiple Sclerosis at the Americas Committee for Treatment and Research in Multiple Sclerosis Annual Forum

GlobeNewswire

7 hours ago

uniQure Announces Updated Preliminary AMT-191 Phase I/IIa Data Showing Sustained Increases in α-Gal A Enzyme Activity in Patients with Fabry Disease

GlobeNewswire

7 hours ago

Pulmovant Announces Completion of Enrollment in the Phase 2 PHocus Study of Mosliciguat in Patients with Pulmonary Hypertension Associated with Interstitial Lung Disease (PH-ILD)

GlobeNewswire